A new, efficient, two step procedure for the preparation of the antineoplastic agent sparfosic acid

Synthetic Communications

Volumn 27, Issue 7, 1997, Pages 1259-1266

  Morris, Angela D ^a   Cordi, Alex A ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

SPARFOSIC ACID;

ARTICLE; DRUG IDENTIFICATION; DRUG SYNTHESIS; IN VITRO STUDY; INFRARED SPECTROPHOTOMETRY; NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS;

EID: 0030945932     PISSN: 00397911     EISSN: None     Source Type: Journal    
DOI: 10.1080/00397919708003363     Document Type: Article

References (30)

1. (a) Farrington, G.K.; Kumar, A.; Wedler, F.C. J. Med. Chem. 1985, 28, 1668;
2. (b) Kafarski, P.; Lejczak, B.; Mastalerz, P.; Dus, D.; Radzikowski, C. J. Med. Chem. 1985, 28, 1555.
3. (a) Swyryd, E.A.; Seaver, S.S.; Stark, G.R. J. Biol. Chem. 1974, 249, 6945;
4. (b) Johnson, R.K.; Inowye, T.; Goldin, A.; Stark, G.R. Cancer Res. 1976, 36, 2720; Weber, G. New Engl. J. Med. 1977, 296, 486.
5. (b) Johnson, R.K.; Inowye, T.; Goldin, A.; Stark, G.R. Cancer Res. 1976, 36, 2720; Weber, G. New Engl. J. Med. 1977, 296, 486.
6. (a) Gleissner, B.; Wadler, S.; Hilgenfeld, R.; Schwartz, S.; Thiel, E., Kreuser, E.D Ann. Oncol. 1994, 5, abst. 442;
7. (b) Ardalan, B.; Donofrio, K.; Livingstone, A.; Reddy, R.; Richman, S.; Sridhar, K.S.; Benedetto, P., Morrell, L.; Miller, C.L.; Feun, L. Proc. Amer. Soc. Clin. Oncol. 1995, 14, abst. 558;
8. (c) Hageboutros, A.; Hudes, G.R.; Brennan, J.; Green, F.; Hoffman, J.; Lacreta, F.P.; Colofiore, J.; Martin, D.S.; Ozols, R.F.; O'Dwyer, P.J. Cancer Chemother. Pharmacol. 1996, 37, 229.
9. Shipkowitz, N.L.; Bower, R.R.; Appel, R.N.; Nordeen, C.W.; Overb, L.R.; Roderick, W.R.; Schleicher, J.B.; VON Esch, A.M. Appl. Microbiol. 1973, 26, 264.
10. (a) Wyde, P.R.; Moore, D.K.; Pimentel, D.M.; Blough, H.A. Antivir. Res. 1995, 27, 59;
11. (b) Blough, H.A. World Patent 18762 1993.
12. (a) Parsons, J.L.; Dubicki, H. US Patent 4154759 1979;
13. (b) Parsons, J.L. US Patent 4178306 1980;
14. (c) Schultz, R.J.; Starks, F.W. US Patent 4215070 1981;
15. (d) Henklein, P.; Gloede, J.; Gross, H.; Tschiersch, B.; Klose, A.; Winterfeld, G.; Steinke, W.; Niedrich, H. German Patent 272092 1990;
16. (e) Stiebitz, B.; Moegelin, W.; Balszuweit, A.; Issleib, K. German Patent 286589 1991.
17. (a) Goodson, J.J.; Wharton, C.J.; Wrigglesworth, R. J.C.S. Perkin Tans. 1 1981, 2721;
18. (b) Montero, J.-L.; Imbach, J.-L. Eur. J. Med. Chem. 1982, 17, 97;
19. (c) Kafarski, P.; Soroka, M. Synthesis 1982, 219;
20. (d) Gigot, D.; Penninckx, M. J. Pharm. Sci. 1984, 73, 275;
21. (e) Tschiersch, B. Pharmazie 1988, 43, 434.
22. The exception to this is ref. 6e.
23. For example see ref. 1, 6e, 7a-c.
24. 6e whereupon purification by distillation or anhydrous chromatography became obligatory.
25. McKenna, C.E.; Higa, M.T.; Cheung, N.H.; McKenna, M.-C. Tetrahedron Lett. 1977, 18, 155.
26. McKenna, C.E.; Schmidhauser, J. J.C.S. Chem. Comm. 1979, 739.
27. Salomon, C.J.; Breuer, E. Tetrahedron Lett. 1995, 36, 6759.
28. Chakravarty, P.K.; Combs, P.; Roth, A.; Greenlee, W.J. Tetrahedron Lett. 1987, 28, 611.
29. Demaine, D.A.; Smith, S.; Barraclough, P. Synthesis, 1992, 1065.
30. 1H NMR and reverse phase HPLC analysis.